Repeat Cytoreductive Surgery for Colorectal Cancer Metastatic to the Peritoneal Cavity.

ABSTRACT:

Introduction

Colorectal cancer (CRC) is a leading cause of cancer-related death worldwide. 5-15% of CRC patients develop peritoneal metastases (PM), and those with PM have poor prognosis. For patients with new CRC-related PM, surgical treatment, including cytoreductive surgery (CRS) with/without hyperthermic intraperitoneal chemotherapy (HIPEC) has been shown to improve survival compared with systemic therapy alone; however, little is known about the benefits of re-do CRS for recurrent PM.

Methods

All CRC patients who underwent CRS with/without HIPEC (2008-2023) were retrospectively identified at one major referral center. Clinicodemographic variables were extracted by chart review. Recurrence-free survival (RFS), peritoneal disease-free survival (PDFS), and overall survival

SUBMITTER: Marincola Smith P 

PROVIDER: S-EPMC12550768 | biostudies-literature | 2026 Mar

REPOSITORIES: biostudies-literature